First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
LEO Pharma is developing delgocitinib cream for the treatment of moderate to severe chronic hand eczema, a hard-to-treat disease where there is a high unmet medical need for treatment
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
UTD2 is the world's first oral epothilone microtubule inhibitor
Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)
Subscribe To Our Newsletter & Stay Updated
